Thinly traded micro cap Innate Pharma S.A. (NASDAQ:IPHA) jumps 39% premarket on modest volume in apparent reaction to an article in Nature from
a group of Chinese scientists that the number of certain immune cells, T
lymphocytes and natural killer cells, decrease significantly in
patients with SARS-CoV-2 infection with increased expression of a
receptor called NKG2A. In recovering patients, however, the numbers of
NK and CD8+T cells were restored with reduced expression of NKG2A.
The company’s lead drug monalizumab,
in Phase 2 development for the treatment of a range of cancers, is a
humanized IgG4 antibody that binds to (inhibits) the NKG2A receptor,
allowing the activation of NK and T cell responses, hence its potential
in treating COVID-19.
AstraZeneca (NYSE:AZN) in-licensed exclusive global oncology rights in October 2018.
https://seekingalpha.com/news/3554139-innate-pharma-up-39-premarket-on-potential-use-of-cancer-drug-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.